Multimodal imaging of prostate cancer

Authors

DOI:

https://doi.org/10.22141/2307-1257.9.1.2020.196920

Keywords:

magnetic resonance imaging, positron emission tomography, radiopharmaceutical, prostate cancer, review

Abstract

The literature review presents key issues of the clinical application of multimodal imaging methods in prostate cancer. The world scientific community at the present stage exerts intensive efforts to develop risk stratification tools to help making clinical decisions and optimizing the care of patients with prostate cancer. Multimodal imaging plays a key role in the management of prostate cancer patients for its non-invasive approach to assessing the pre­sence and extent of the primary tumor process, metastatic spread. A promising area of nuclear medicine, theranostics, is being actively introduced into clinical practice. The basic principle of the­ranostics is to “see that you are treating” by combining diagnostic markers with therapeutic radioligands.

Downloads

Download data is not yet available.

References

Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK. Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018;36(8):349–360. doi:10.1016/j.urolonc.2018.05.008.

Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44(5):776–787. doi:10.1007/s00259-016-3594-z.

Korol P, Tkachenko M. The role of radioactive methods in the diagnostic type of hydronephrosis in clean-up workers of chornodil accident. Problems of radiation medicine and radiobiology. 2018;23:351–358. doi:0.33145/2304-8336-2018-23-351-358 (in Ukrainian).

Park SY, Zacharias C, Harrison C, et al. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Radiology. 2018;288(2):495–505. doi:10.1148/radiol.2018172232.

Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–1777. DOI: 10.1056/NEJMoa1801993.

Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med. 2004;45(9):1509–1518.

Armstrong AJ, Anand A, Edenbrandt L, et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018;4(7):944–951. doi:10.1001/jamaoncol.2018.1093.

von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45(3):496–508. doi:10.1007/s00259-017-3895-x.

Fanti S, Minozzi S, Antoch G, et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018;19(12):e696–e708. doi:10.1016/S1470-2045(18)30604-1.

Metser U, Chua S, Ho B, et al. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. J Nucl Med. 2019;60(9):1253–1258. doi:10.2967/jnumed.118.225185.

Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2017;71(1):81–92. doi:10.1016/j.eururo.2016.05.033.

Zacho HD, Nielsen JB, Afshar-Oromieh A, et al. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1884–1897. doi:10.1007/s00259-018-4058-4.

Padhani AR, Lecouvet FE, Tunariu N, et al. Rationale for Modernising Imaging in Advanced Prostate Cancer. Eur Urol Focus. 2017;3(2-3):223–239. doi:10.1016/j.euf.2016.06.018.

Donohoe KJ, Cohen EJ, Giammarile F, et al. Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts. J Nucl Med. 2017;58(4):14N–17N.

Wibmer AG, Burger IA, Sala E, Hricak H, Weber WA, Vargas HA. Molecular Imaging of Prostate Cancer. Radiographics. 2016;36(1):142–159. doi:10.1148/rg.2016150059.

Jadvar H. Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016;46(6):502–506. doi:10.1053/j.semnuclmed.2016.07.004.

Shen G, Liu J, Hao Z, et al. Is18F-FDG PET/CT a useful tool in prostate cancer? J Nucl Med. 2017;58(Suppl 1):1077.

Vargas HA, Wassberg C, Fox JJ, et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014;271(1):220–229. doi:10.1148/radiol.13130625.

Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0 [published correction appears in J Nucl Med. 2011 Mar;52(3):495]. J Nucl Med. 2010;51(11):1813–1820. doi:10.2967/jnumed.110.082263.

Löfgren J, Mortensen J, Rasmussen SH, et al. A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases. J Nucl Med. 2017;58(11):1778–1785. doi:10.2967/jnumed.116.189183.

Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics. 2012;2(3):318–330. doi:10.7150/thno.4008.

Hodolic M. Role of (18)F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol. 2011;45(1):17–21. doi:10.2478/v10019-010-0050-8.

Calais J, Ceci F, Nguyen K, et al. Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer bio-chemical recurrence after primary prostatectomy. J Clin Oncol. 2019;37(suppl):15. doi: 10.1200/JCO.2019.37.7_suppl.15.

Burger IA, Müller J, Donati OF, et al. 68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. J Nucl Med. 2019;60(8):1118–1123. doi:10.2967/jnumed.118.221564.

Schuster DM, Savir-Baruch B, Nieh PT, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259(3):852–861. doi:10.1148/radiol.11102023.

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–2261. doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s.

Oh SW, Cheon GJ. Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean J Radiol. 2018;19(5):819–831. doi:10.3348/kjr.2018.19.5.819.

Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5(10):2674–2681.

Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med. 2019;60(2):185-191. doi:10.2967/jnumed.118.214833.

Giesel FL, Knorr K, Spohn F, et al. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2019;60(3):362–368. doi:10.2967/jnumed.118.212233.

Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 2013;19(1):43–49. doi:10.1097/PPO.0b013e318282635a.

Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45(3):366–373.

Vargas HA, Kramer GM, Scott AM, et al. Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med. 2018;59(10):1516–1523. doi:10.2967/jnumed.117.206490.

Eiber M, Weirich G, Holzapfel K, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol. 2016;70(5):829–836. doi:10.1016/j.eururo.2015.12.053.

Hicks RM, Simko JP, Westphalen AC, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology. 2018;289(3):730–737. doi:10.1148/radiol.2018180788.

Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186(5):1818–1824. doi:10.1016/j.juro.2011.07.013.

Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16–40. doi:10.1016/j.eururo.2015.08.052.

Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi:10.1016/S0140-6736(16)32401-1.

Moldovan PC, Van den Broeck T, Sylvester R, et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017;72(2):250–266. doi:10.1016/j.eururo.2017.02.026.

Mohammadian Bajgiran A, Afshari Mirak S, Shakeri S, et al. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. Abdom Radiol (NY). 2019;44(3):1052–1061. doi:10.1007/s00261-018-1823-6.

Borofsky S, George AK, Gaur S, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. 2018;286(1):186–195. doi:10.1148/radiol.2017152877.

Sala E, Akin O, Moskowitz CS, et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology. 2006;238(3):929–937. doi:10.1148/radiol.2383050657.

de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2016;70(2):233–245. doi:10.1016/j.eururo.2015.07.029.

Mühlematter UJ, Becker KSA, Müller J, et al. Detection of extracapsular extension in high risk prostate cancer patients: multiparametric MRI vs.68Ga-PSMA-11 PET/MRI. Paper presented at: 2019 European Congress of Radiology; February 28, 2019; Vienna, Austria.

Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?. Am J Surg Pathol. 2012;36(9):1346–1352. doi:10.1097/PAS.0b013e3182556dcd.

Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61(3):480–487. doi:10.1016/j.eururo.2011.10.044.

Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–875. doi:10.1016/j.juro.2010.10.057.

Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–395. doi:10.1016/j.crad.2007.05.022.

Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63(6):1040–1048. doi:10.1016/j.eururo.2012.09.039.

Hofman MS, Murphy DG, Williams SG, et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018;122(5):783–793. doi:10.1111/bju.14374.

Selnæs KM, Krüger-Stokke B, Elschot M, et al. 18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur Radiol. 2018;28(8):3151–3159. doi:10.1007/s00330-017-5213-1.

Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clin Cancer Res. 2018;24(24):6300–6307. doi:10.1158/1078-0432.CCR-18-0768.

Giesel FL, Fiedler H, Stefanova M, et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(12):1794–1800. doi:10.1007/s00259-015-3106-6.

Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436–1443. doi:10.1016/j.juro.2015.12.025.

Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–1418. doi:10.1200/JCO.2015.64.2702.

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737–746. doi:10.1056/NEJMoa1503747.

Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(12):2114–2121. doi:10.1007/s00259-016-3435-0.

Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–629. doi:10.1016/j.eururo.2016.08.003.

Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014;66(3):479–486. doi:10.1016/j.eururo.2013.11.045.

Oppenheimer DC, Weinberg EP, Hollenberg GM, Meyers SP. Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer. J Clin Imaging Sci. 2016;6:18. Published 2016 Apr 29. doi:10.4103/2156-7514.181494.

Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol. 2011;21(9):1970–1978. doi:10.1007/s00330-011-2130-6. 

Donati OF, Jung SI, Vargas HA, et al. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?. Radiology. 2013;268(2):440–450. doi:10.1148/radiol.13122149.

Wu LM, Xu JR, Gu HY, et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol). 2013;25(4):252–264. doi:10.1016/j.clon.2012.11.010.

Sandgren K, Westerlinck P, Jonsson JH, et al. Imaging for the Detection of Locoregional Recurrences in Biochemical Progression After Radical Prostatectomy-A Systematic Review. Eur Urol Focus. 2019;5(4):550–560. doi:10.1016/j.euf.2017.11.001.

Barchetti F, Stagnitti A, Megna V, et al. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci. 2016;20(18):3770–3776.

Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi:10.1007/s00259-013-2525-5.

Tan N, Bavadian N, Calais J, et al. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. J Urol. 2019;202(2):231–240. doi:10.1097/JU.0000000000000198.

Bravaccini S, Puccetti M, Bocchini M, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018;8(1):4254. Published 2018 Mar 9. doi:10.1038/s41598-018-22594-1.

Andriole GL, Kostakoglu L, Chau A, et al. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. J Urol. 2019;201(2):322–331. doi:10.1016/j.juro.2018.08.050.

Jilg CA, Drendel V, Rischke HC, et al. Detection Rate of 18F-Choline PET/CT and 68Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. J Nucl Med. 2019;60(7):971–977. doi:10.2967/jnumed.118.220541.

Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856–863. doi:10.1001/jamaoncol.2019.0096.

Fox JJ, Gavane SC, Blanc-Autran E, et al. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2018;4(2):217–224. doi:10.1001/jamaoncol.2017.3588.

Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. J Nucl Med. 2016;57(Suppl 3):73S–78S. doi:10.2967/jnumed.115.170134.

Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer [published correction appears in J Nucl Med. 2018 Feb;59(2):346]. J Nucl Med. 2017;58(8):1196–1200. doi:10.2967/jnumed.117.191023.

Ghafoor S, Burger IA, Vargas AH. Multimodality Imaging of Prostate Cancer. J Nucl Med. 2019;60(10):1350–1358. doi:10.2967/jnumed.119.228320.

Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58(1):85–90. doi:10.2967/jnumed.116.183194.

Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–833. doi:10.1016/S1470-2045(18)30198-0.

Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T. The Molecular Evolution of Castration-resistant Prostate Cancer. Eur Urol Focus. 2016;2(5):506–513. doi:10.1016/j.euf.2016.11.012.

Heitkötter B, Steinestel K, Trautmann M, et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018;9(11):9867–9874. Published 2018 Jan 4. doi:10.18632/oncotarget.23984.

Pezaro C, Omlin A, Lorente D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270–273. doi:10.1016/j.eururo.2013.10.055.

Korol PA, Tkachenko MM. Modern trends in radionuclide diagnostics and therapy of patients with prostate cancer. Radiation Diagnostics, Radiation Therapy. 2018;(3):58-69. (in Ukraine).

Downloads

Published

2021-09-08

How to Cite

Korol, P., Tkachenko, M., & Shcherbina, O. (2021). Multimodal imaging of prostate cancer. KIDNEYS, 9(1), 68–79. https://doi.org/10.22141/2307-1257.9.1.2020.196920

Issue

Vol. 9 No. 1 (2020)

Section

Reviews

License

Copyright (c) 2020 P.O. Korol, M.M. Tkachenko, O.V. Shcherbina

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.